EVALUATION OF USAGE MEDICAMENTS FOR TREATMENT OF GASTROINTESTINAL TRACT AND METABOLISM AND TREATMENT OF MUSCULAR AND SCELETAL SYSTEM DISEASES ON THE BASIS OF DEFINED DAILY DOSE

M. Vojnović ,
M. Vojnović

The Health centre , Novi Sad , Serbia

Đ. Jakovljević ,
Đ. Jakovljević

Institute for cardiovascular diseases , Sremska Kamenica , Serbia

V. Jakovljević ,
V. Jakovljević

Department of pharmacologi and toxicology, Medical faculty Novi Sad , Novi Sad , Serbia

M. Stanulović ,
M. Stanulović

Department of pharmacologi and toxicology, Medical faculty Novi Sad , Novi Sad , Serbia

V. Pilija
V. Pilija

Department of anatomy, Medical faculty Novi Sad , Novi Sad , Serbia

Published: 01.01.2005.

Volume 33, Issue 1 (2005)

pp. 49-54;

https://doi.org/10.70949/pramed200501112V

Abstract

Defined daily dose (DDD) is arbitrary chosen technical unit for measuring medicament usage and it is not a recommended therapeutic dose. It is in fact a statistical parameter for monitoring medicaments usage, and it is related to the
dose which is usually prescribed for the indication that the medicament was registered for. The aim of this work is to perform a detailed analysis of the extent and structure of the region of South Backa. According to the obteined data, medicaments
used in treatment of gastroinestinal tract contributed with 15.52 DDD/1000 inhabitants per day. Most commonly used are antacids and anti-ulcer drugs (8.14 DDD/1000 inhabitants per day). Medicaments used in treatment of muscular and skeletal
system contributed with 14.30 DDD/1000 inhabitants per day. Antiinflammatory and antirheumatic drugs sre used in amounts of 14.18 DDD/1000 inhabitants per day. In our country there is no complex survey of drug usage because there is no way of monitor ing which could apprehend all possible information sources. Defined daily dose is not introduced into practical qualitative and quantitative monitoring. It is necessary to make systematic network of information sources to provide for insight into medicament usage

Keywords

References

1.
Lane M, Lee S. Recurrence of duodenal ulcer after medical treatment. Lancet. 1:659–75.
2.
Laakso M, Reunanen A, Klaukka T, Aromaa A, Maatela J, Pyorala K. Changes in the prevalence and incidence of diabetes mellitus in Finnish adults, 1970-1987. American Journal of Epidemiology. 133:850–7.
3.
Lichtenstein DR, Wolfe MM. COX-2-Selective NSAIDs. Journal of the American Medical Association. 284:1297–9.
4.
O’Brien J, Burnham W. Bleeding from peptic ulcers and use of nonsteroidal anti-inflammatory drugs in Romford area. British Medical Journal. 291:1609–10.
5.
Guess H, West R, Strand L. Fatal upper gastrointestinal hemorrhage or perforation among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada. Journal of Clinical Epidemiology. 41:35–45.
6.
Guess H, West R, Strand L, Helston D, Lydick E, Bergman U, et al. Hospitalization for renal impairment among users and non-users of non-steroidal anti-inflammatory drugs in Saskatchewan, Canada. In: Proceedings of the 2nd International Meeting on the Side-effects of Anti-inflammatory Analgesic Drugs.
7.
Ahonen R, Enlund H, Klaukka T, Martikainen J. Consumption of analgesics and anti-inflammatory drugs in Nordic countries between 1978-1988. European Journal of Clinical Pharmacology. 41(1):37–43.
8.
Lunde PKM. Drug utilization studies, a useful tool for the safety evaluations of NSAIDs. In: Proceedings of the 2nd International Meeting on the Side-effects of Anti-inflammatory Analgesic Drugs.
9.
Brooks P, Day R. Nonsteroidal anti-inflammatory drugs: Differences and similarities. New England Journal of Medicine. 324:1716–25.
10.
Stanulović M, Jakovljević V, Kovač T, Lepšanović L, Dučić M. Regional and international comparison in utilization of antidiabetic drugs. International Journal of Clinical Pharmacology, Therapeutics and Toxicology. 24:254–6.
11.
Jakovljević V, Sabo A, Stanulović M, Popović M, Rončević N. Propisivanje vitaminskih preparata deci u vanbolničkim i bolničkim ustanovama.
12.
Jakovljević V, Stanulović M. Upotreba lekova u Novom Sadu 1984. Pharmaca. 24:9–19.
13.
Kiivet RA, Bergman U, Rootslane L, Rgo L, Sjqvist F. Drug use in Estonia in 1994-1995: A follow-up from 1989 and comparison with two Nordic countries. European Journal of Clinical Pharmacology. 54:119–24.
14.
Sakshaud S. Drug Utilization in Norway during the 1970s.
15.
Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a Medicine Review and Education Programme for Older People in General Practice. British Journal of Clinical Pharmacology. 50:172–5.
16.
Lunde PKM. Criteria for Rational Drug Therapy. In: Auditing Drug Therapy. p. 18–29.
17.
Laaketilasto S. Finnish Statistics on Medicines 1996.
18.
Beograd E. More Rational Drug Utilization in Primary Health Care in FR Yugoslavia.
19.
Laurence DR, Bennett PN, Brown MJ. Clinical Pharmacology.
20.
Reference PD.
21.
Avers’s Drug Treatment.
22.
Formulary BN.
23.
Tomić Z, Čanković S, Stanulović M. Farmakoepidemiologija: Proučavanje upotrebe lekova sa ATC klasifikacijom.
24.
Wiholm BE. Epidemiological Methods and Systems for Auditing Adverse Drug Reactions. In: Auditing Drug Therapy. p. 47–59.
25.
Menniti-Ippolito F, Maggini M, Raschetti R, Cas G, Traversa AM, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: A comparison with other non-steroidal anti-inflammatory drugs in Italy. European Journal of Clinical Pharmacology. 54:393–7.
26.
Štritof M, Milunić-Bayers M, Radmilović M. Upotreba lijekova koji djeluju na bolesti mišićno-koštanog sistema i vezivnog tkiva. Pharmaca. 28:29–36.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by